Inventor · disambiguated record
Roger S. Flugel
Also filed as: FLUGEL ROGER S
6 granted patents·19 pending applications·29 citations·filing 2011–2018
82Inventor score
Top patents by PatentIndex Score
25 records- 0183US9132124B2Combinations of solifenacin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Granted Sep 15, 2015·7 cites·6 claims
- 0283US8940763B2Combinations of solifenacin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Granted Jan 27, 2015·7 cites·11 claims
- 0382US9968556B2Pharmaceutical formulationsTHERAVIDA INC·Filed 2016·Granted May 15, 2018·4 cites·19 claims
- 0482US9744157B2Combinations of solifenacin and salivary stimulants for the treatment of overactive bladderTHERAVIDA INC·Filed 2015·Granted Aug 29, 2017·4 cites·6 claims
- 0581US10786457B2Pharmaceutical formulationsTHERAVIDA INC·Filed 2018·Granted Sep 29, 2020·1 cites·30 claims
- 0680US9415013B2Pharmaceutical formulationsPABORJI MEHDI·Filed 2011·Granted Aug 16, 2016·6 cites·19 claims
- 0759US2014194454A1Combinations of trospium and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2014·Application pending·0 cites
- 0858US2013296392A1Methods for the treatment of overactive bladderTHERAVIDA INC·Filed 2013·Application pending·0 cites
- 0955US2012289531A1Combinations of trospium and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1055US2012289529A1Combinations of trospium and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1155US2012289530A1Combinations of trospium and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1255US2012289566A1Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1355US2012289539A1Combinations of trospium and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1454US2017258767A1Methods for the treatment of overactive bladderTHERAVIDA INC·Filed 2016·Application pending·0 cites
- 1554US2012289564A1Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1652US2012201894A1Pharmaceutical formulations for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1746US2012289561A1Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1845US2012289567A1Combinations of darifenacin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 1945US2012289562A1Combinations of darifenacin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2045US2012289560A1Combinations of tolterodine and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2145US2012289565A1Combinations of tolterodine and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2245US2012289547A1Combinations of propiverine and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2345US2012289568A1Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2438US2012289563A1Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladderPABORJI MEHDI·Filed 2012·Application pending·0 cites
- 2536US2011245294A1Methods of improving quality of sleepTHERAVIDA INC·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roger S. Flugel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →